Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society

Clicks: 513
ID: 113043
1999
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #2 of 28 articles by views in Blood

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
The familial form of hemophagocytic lymphohistiocytosis (HLH) is a lethal disorder. Although the prognosis for Epstein-Barr virus-associated HLH (EBV-HLH) remains uncertain, numerous reports indicate that it can also be fatal in a substantial proportion of cases. We therefore assessed the potential …
Reference Key
s1999bloodeffective Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Imashuku S;Hibi S;Ohara T;Iwai A;Sako M;Kato M;Arakawa H;Sotomatsu M;Kataoka S;Asami K;Hasegawa D;Kosaka Y;Sano K;Igarashi N;Maruhashi K;Ichimi R;Kawasaki H;Maeda N;Tanizawa A;Arai K;Abe T;Hisakawa H;Miyashita H;Henter JI;;
Journal Blood
Year 1999
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.